MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Search

Cytek Biosciences Inc

Отворен

СекторЗдравеопазване

4.6 -2.75

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.45

Максимум

4.6899999999999995

Ключови измерители

By Trading Economics

Приходи

-39M

-44M

Продажби

9.8M

62M

Марж на печалбата

-70.929

Служители

702

EBITDA

4M

-263K

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+35.87% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

20M

581M

Предишно отваряне

7.35

Предишно затваряне

4.6

Настроения в новините

By Acuity

50%

50%

168 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Cytek Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.04.2026 г., 20:44 ч. UTC

Печалби

Costco Reports 11% Growth in March Sales

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8.04.2026 г., 23:36 ч. UTC

Пазарно говорене
Значими събития в новините

Gold Edges Lower on Likely Technical Correction -- Market Talk

8.04.2026 г., 22:56 ч. UTC

Пазарно говорене

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8.04.2026 г., 22:45 ч. UTC

Пазарно говорене

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8.04.2026 г., 21:52 ч. UTC

Значими събития в новините

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8.04.2026 г., 21:24 ч. UTC

Печалби

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8.04.2026 г., 21:01 ч. UTC

Значими събития в новините

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Responds to TRC Cap Mini-Tender Offer

8.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8.04.2026 г., 19:44 ч. UTC

Печалби

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8.04.2026 г., 19:16 ч. UTC

Пазарно говорене

Hogs Follow Cutout Prices Lower -- Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8.04.2026 г., 18:58 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8.04.2026 г., 18:14 ч. UTC

Значими събития в новините

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8.04.2026 г., 18:05 ч. UTC

Значими събития в новините

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Cytek Biosciences Inc Прогноза

Ценова цел

By TipRanks

35.87% нагоре

12-месечна прогноза

Среден 6.25 USD  35.87%

Висок 7.5 USD

Нисък 5 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytek Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

3.7 / 3.8Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

168 / 349 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat